Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.65
+0.05 (0.89%)
At close: May 6, 2026, 4:00 PM EDT
5.60
-0.05 (-0.88%)
After-hours: May 6, 2026, 6:09 PM EDT
Atea Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Atea Pharmaceuticals stock has a target of 10, which predicts a 76.99% increase from the current stock price of 5.65.
Price Target: $10 (+76.99%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 9, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Atea Pharmaceuticals is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +76.99% | Mar 9, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $6.2 → $6 | Hold | Maintains | $6.2 → $6 | +6.19% | Apr 11, 2025 |
| Morgan Stanley | Morgan Stanley | Sell → Hold Upgrades $2 → $6.88 | Sell → Hold | Upgrades | $2 → $6.88 | +21.77% | Aug 13, 2024 |
| JP Morgan | JP Morgan | Hold → Sell Downgrades n/a | Hold → Sell | Downgrades | n/a | n/a | Aug 10, 2023 |
| JP Morgan | JP Morgan | Hold Maintains $12 → $8 | Hold | Maintains | $12 → $8 | +41.59% | Mar 16, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.07M
EPS This Year
-1.69
from -1.94
EPS Next Year
-1.69
from -1.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 64.0M | |
| Avg | n/a | 31.1M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.74 | -1.74 | |
| Avg | -1.69 | -1.69 | |
| Low | -1.63 | -1.63 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.